Literature DB >> 30965239

Dexmedetomidine preconditioning attenuates ischemia/reperfusion injury in isolated rat hearts with endothelial dysfunction.

Liang He1, Shuqing Hao2, Yanqiong Wang2, Wei Yang2, Lan Liu3, Hongmei Chen4, Jinqiao Qian5.   

Abstract

BACKGROUND AND PURPOSES: Dexmedetomidine preconditioning (DP) can mimic pharmacological preconditioning and induce cardiac protection. There are controversies on the roles of coronary endothelia in cardioprotection of dexmedetomidine. Herein, we tested the hypothesis that protection of dexmedetomidine is not endothelial dependent in heart against myocardial ischemia/reperfusion (I/R) injury.
METHODS: Langendorff-perfused rat hearts were pretreated by 60 mM of potassium to produce endothelial dysfunction (ED), then medicated with dexmedetomidine, and subsequently subjected to 30 min of global ischemia followed by 60 min of reperfusion. To investigate the cardioprotective effect of dexmedetomidine in heart with ED, isolated rat hearts were randomly divided into the following six groups: sham, I/R, DP, ED, ED + I/R, and ED + DP + I/R. Heart rates, left ventricular function, and coronary perfusion pressure were assessed for each heart. Infarct size was evaluated by triphenyltetrazolium chloride staining. High-sensitivity cardiac troponin T (hs-cTNT) of coronary flow perfusion was determined.
RESULTS: After the isolated hearts with pretreatment of 60 mM of potassium chloride, diastolic function of coronary endothelia in performance of response to histamine was significantly decreased (P < 0.05). DP attenuated I/R-induced infarct size of the left ventricle (P < 0.05) and decreased hs-cTNT (P < 0.05). Additionally, left ventricular developed pressure, +dp/dtmax, and -dp/dtmax were elevated in rat hearts pretreated with dexmedetomidine. Furthermore, dexmedetomidine-mediated cardiac protection against I/R injury was still remained in isolated hearts with coronary ED.
CONCLUSION: Continuous perfusion of 60 mM of potassium for 10 min can produce coronary ED in isolated rat hearts. Dexmedetomidine maintains its protective function against I/R injury in heart with coronary ED. Myocardial protection of dexmedetomidine is non-endothelial function dependent in alleviating I/R injury.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Dexmedetomidine; Ischemia/reperfusion; Preconditioning; hs-cTNT

Mesh:

Substances:

Year:  2019        PMID: 30965239     DOI: 10.1016/j.biopha.2019.108837

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

1.  Dexmedetomidine alleviates cardiomyocyte apoptosis and cardiac dysfunction may be associated with inhibition of RhoA/ROCK pathway in mice with myocardial infarction.

Authors:  Tao Sun; Qian Gong; Ying Wu; Zhiming Shen; Yan Zhang; Shenglin Ge; Jing-Si Duan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-03-29       Impact factor: 3.000

2.  Up-regulating microRNA-138-5p enhances the protective role of dexmedetomidine on myocardial ischemia-reperfusion injury mice via down-regulating Ltb4r1.

Authors:  Yanzi Chang; Lika Xing; Wenjuan Zhou; Wei Zhang
Journal:  Cell Cycle       Date:  2021-01-28       Impact factor: 4.534

Review 3.  [Perioperative cardioprotection - From bench to bedside : Current experimental evidence and possible reasons for the limited translation into the clinical setting].

Authors:  Carolin Torregroza; Sebastian Roth; Katharina Feige; Giovanna Lurati Buse; Markus W Hollmann; Ragnar Huhn
Journal:  Anaesthesist       Date:  2021-01-19       Impact factor: 1.041

4.  Dexmedetomidine reduces enteric glial cell injury induced by intestinal ischaemia-reperfusion injury through mitochondrial localization of TERT.

Authors:  Qian Hu; Xiao-Ming Liu; Zheng-Ren Liu; Zhi-Yi Liu; Huai-Gen Zhang; Qin Zhang; Yuan-Lu Huang; Qiu-Hong Chen; Wen-Xiang Wang; XueKang Zhang
Journal:  J Cell Mol Med       Date:  2022-04-02       Impact factor: 5.295

5.  Role of Keap1-Nrf2/ARE signal transduction pathway in protection of dexmedetomidine preconditioning against myocardial ischemia/reperfusion injury.

Authors:  Hui-Xian Li; Tai-Hang Wang; Lin-Xin Wu; Fu-Shan Xue; Guo-Hua Zhang; Tao Yan
Journal:  Biosci Rep       Date:  2022-09-30       Impact factor: 3.976

Review 6.  Amelioration of myocardial ischemia/reperfusion injury in diabetes: A narrative review of the mechanisms and clinical applications of dexmedetomidine.

Authors:  Meng Sun; Rong Wang; Rui Xia; Zhengyuan Xia; Zhilin Wu; Tingting Wang
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

7.  Dexmedetomidine Attenuates Neurotoxicity in Developing Rats Induced by Sevoflurane through Upregulating BDNF-TrkB-CREB and Downregulating ProBDNF-P75NRT-RhoA Signaling Pathway.

Authors:  Yunxia Dong; Wei Hong; Zhiyin Tang; Yan Gao; Xiuying Wu; Hongtao Liu
Journal:  Mediators Inflamm       Date:  2020-06-20       Impact factor: 4.711

8.  Dexmedetomidine Attenuates Cellular Injury and Apoptosis in H9c2 Cardiomyocytes by Regulating p-38MAPK and Endoplasmic Reticulum Stress.

Authors:  Zhipeng Zhu; Xiaoyan Ling; Hongmei Zhou; Caijun Zhang; Weiwei Yan
Journal:  Drug Des Devel Ther       Date:  2020-10-12       Impact factor: 4.162

Review 9.  Pharmacological Conditioning of the Heart: An Update on Experimental Developments and Clinical Implications.

Authors:  Sebastian Roth; Carolin Torregroza; Katharina Feige; Benedikt Preckel; Markus W Hollmann; Nina C Weber; Ragnar Huhn
Journal:  Int J Mol Sci       Date:  2021-03-03       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.